Front cover image for Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Peer-reviewed

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer

Article, 2010
The New England journal of medicine, 363, 20100729, 411
2010